Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development

Autor: I. J. Frame, Myles H. Akabas, Yvett Sosa, Roman Deniskin

Publikováno v: International Journal for Parasitology: Drugs and Drug Resistance, Vol 6, Iss 1, Pp 1-11 (2016)
International Journal for Parasitology: Drugs and Drug Resistance

Infection with Plasmodium falciparum and vivax cause most cases of malaria. Emerging resistance to current antimalarial medications makes new drug development imperative. Ideally a new antimalarial drug should treat both falciparum and vivax malaria.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d369a70028fd3fb4d411b54bb547d0d
https://doi.org/10.1016/j.ijpddr.2015.11.003

Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development.

Autor: Deniskin R; Department of Physiology & Biophysics, Albert Einstein College of Medicine, Bronx, New York, USA., Frame IJ; Department of Physiology & Biophysics, Albert Einstein College of Medicine, Bronx, New York, USA., Sosa Y; Department of Physiology & Biophysics, Albert Einstein College of Medicine, Bronx, New York, USA., Akabas MH; Department of Physiology & Biophysics, Albert Einstein College of Medicine, Bronx, New York, USA; Department of Neuroscience, Albert Einstein College of Medicine, Bronx, New York, USA; Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA. Electronic address: myles.akabas@einstein.yu.edu.

Publikováno v: International journal for parasitology. Drugs and drug resistance [Int J Parasitol Drugs Drug Resist] 2015 Nov 28; Vol. 6 (1), pp. 1-11. Date of Electronic Publication: 2015 Nov 28 (Print Publication: 2016).